Skip to content

Homepage

$Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026$

Author: Stelexis BioSciences, Inc.

Posted Date:

June 2, 2026

Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026

Stelexis BioSciences, Inc.

June 2, 2026